As commercial payors lag behind Medicare in addressing reimbursement for those diagnosed with cognitive impairments under the age of 65, more than 200,000 Americans under the age of 65 live with Alzheimer's.
This episode, titled 'Designing a Better Managed Care Benefit for Alzheimer's Disease,' featured he expert neurology and...
Over 6 million Americans, including 150,000 Arizonans are currently living with Alzheimer's Disease. As the need for treatment grows, groups like the Alzheimer's Association are asking the government to strengthen its commitment to research and accessibility. But a Congressional report suggests the U.S. Food and Drug Administration (FDA)...
Following approval by the Food and Drug Administration (FDA) last year, the Centers for Medicare and Medicaid (CMS) proposed last month to cover the Alzheimer’s disease drug Aduhelm only for beneficiaries enrolled in a clinical trial. The proposal has sparked fierce debate among insurance groups, drugmakers, policymakers and the...
The Centers for Medicare and Medicaid Services (CMS) proposed Tuesday to cover the controversial drug Aduhelm when used as an Alzheimer’s treatment in clinical trials. While debate about the drug’s safety has been intense, CMS believes continued clinical trials will address unanswered questions related to the drug’s adverse side...CMS Rules
Last week, the Centers for Medicare and Medicaid Services (CMS) issued a final rule that included changes to the physician fee schedule (PFS) and changes to payments for Medicare Part B. The agency also announced an increase in Part B beneficiary premiums due in part to the authorization of the controversial Alzheimer's drug Aduhelm,...
